n | % | 95% CI | |
Montreal classification | |||
E1 | 2 | 6 | 0 to 14 |
E2 | 10 | 29 | 13 to 44 |
E3 | 23 | 66 | 49 to 82 |
S0 | 6 | 17 | 4 to 30 |
S1 | 2 | 6 | 0 to 14 |
S2 | 7 | 20 | 6 to 34 |
S3 | 20 | 57 | 40 to 74 |
Concomitant medication(s)* | |||
Mesalamine | 10 | 29 | 13 to 44 |
Oral or intravenous corticosteroids | 14 | 40 | 23 to 57 |
Azathioprine | 7 | 20 | 6 to 34 |
Cyclosporine | 6 | 17 | 4 to 30 |
Tumour necrosis factor antagonists | 12 | 34 | 18 to 51 |
Male gender | 19 | 54 | – |
Tobacco use | 1 | 3 | 0 to 9 |
Previous abdominal IBD-related surgery | 0 | – | – |
Mean | SD | |
Simple clinical activity index (Walmsley index) | 6.1 | 4.3 |
Haemoglobin (g/dl) (n=34) | 11.5 | 2.2 |
Haematocrit (g/dl) (n=34) | 34.3 | 5.8 |
Leucocytes (×109/litre) (n=34) | 9.410 | 3.412 |
Platelets (×109/litre) (n=34) | 419 | 148 |
Albumin (g/l) (n=27) | 31.8 | 7.7 |
Total modified Baron score (n=16) | 7.3 | 5.8 |
Median | IQR, 25–75 | |
Patient age at inclusion (years) | 37 | 27.25–45.5 |
Patient age at IBD diagnosis (years) | 29 | 22–35 |
Disease duration at inclusion (months) | 69 | 24–128 |
C reactive protein (mg/l) (n=33) | 13.3 | 2.7–42.4 |
Serum iron (mg/l) (n=33) | 0.33 | 0.22–0.68 |
↵* A patient may receive more than one concomitant medication.